Intensive Glycemic Control Reduces Neurosurgical SSI, 544 Patients
Summary
A randomized controlled trial comparing intensive glycemic control (continuous insulin infusion targeting 140-180 mg/dL) with standard care (subcutaneous insulin targeting 81-180 mg/dL) in 544 neurosurgical patients. The primary outcome is surgical site infection (SSI) occurrence within 90 days post-surgery, with results intended to guide optimal glycemic management strategies for SSI prevention in neurosurgery. Three intervention protocols are being studied: intensive glycemic control, hypokalemia prevention during IV insulin therapy, and glucose-supported intravenous insulin infusion.
“This randomized, controlled trial will compare intensive glycemic control (continuous insulin infusion, 140-180 mg/dL) with standard care (subcutaneous insulin, 81-180 mg/dL) in 544 patients.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry documents a new randomized controlled trial (NCT07548112) investigating whether intensive perioperative glycemic control reduces surgical site infections in neurosurgical patients. The trial will enroll 544 patients and compare two insulin administration protocols over a 90-day postoperative follow-up period.
For healthcare providers and clinical investigators, this trial represents an emerging evidence base regarding optimal blood glucose targets in neurosurgery. Institutions performing neurosurgical procedures may wish to monitor these results as they may inform future SSI prevention protocols and glycemic management standards of care.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effects of Intensive Glycemic Control in the Postoperative Period of Neurosurgical Patients on the Incidence of Surgical Site Infection
N/A NCT07548112 Kind: NA Apr 23, 2026
Abstract
Surgical site infections (SSIs) are frequent complications in neurosurgical patients, often worsened by perioperative hyperglycemia. This randomized, controlled trial will compare intensive glycemic control (continuous insulin infusion, 140-180 mg/dL) with standard care (subcutaneous insulin, 81-180 mg/dL) in 544 patients. The primary outcome is SSI occurrence within 90 days post-surgery. Results aim to guide optimal glycemic management for SSI prevention in neurosurgery.
Conditions: Surgical Site Infection (SSI)
Interventions: Intensive glycemic control, Hypokalemia Prevention Protocol During IV Insulin Therapy, Glucose-Supported Intravenous Insulin Infusion Protocol
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.